Neurotensin (NT) exerts naloxone-insensitive antinociceptive action through its binding to both NTS1 and NTS2 receptors and NT analogs provide...
Array
(
[id_prestablog_news] => 1269
[id_shop] => 1
[date] => 2020-05-01 00:00:00
[date_modification] => 2024-02-09 14:15:12
[langues] => ["1","2"]
[actif] => 1
[slide] => 0
[url_redirect] =>
[average_rating] =>
[number_rating] =>
[author_id] => 1
[featured] => 0
[prim_key] => 2495
[id_lang] => 1
[title] => Pain relief devoid of opioid side effects following central action of a silylate
[paragraph] => Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog
[content] => Authors
P T
Lab
Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Universit
Journal
arXiv
Abstract
Neurotensin (NT) exerts naloxone-insensitive antinociceptive action through its binding to both NTS1 and NTS2 receptors and NT analogs provide stronger pain relief than morphine on a molecular basis. Here, we examined the analgesic/adverse effect profile of a new NT(8-13) derivative denoted JMV2009, in which the Pro10 residue was substituted by a silicon-containing unnatural amino acid silaproline. We first report the synthesis and in vitro characterization (receptor-binding affinity, functional activity and stability) of JMV2009. We next examined its analgesic activity in a battery of acute, tonic and chronic pain models. We finally evaluated its ability to induce adverse effects associated with chronic opioid use, such as constipation and analgesic tolerance or related to NTS1 activation, like hypothermia. In in vitro assays, JMV2009 exhibited high binding affinity for both NTS1 and NTS2, improved proteolytic resistance as well as agonistic activities similar to NT, inducing sustained activation of p42/p44 MAPK and receptor internalization. Intrathecal injection of JMV2009 produced ose-dependent antinociceptive responses in the tail-flick test and almost completely abolished the nociceptive related behaviors induced by chemical somatic and visceral noxious stimuli. Likewise, increasing doses of JMV2009 significantly reduced tactile allodynia and weight bearing deficits in nerve injured rats. Importantly, repeated agonist treatment did not result in the development of analgesic tolerance. Furthermore, JMV2009 did not cause constipation and was ineffective in inducing hypothermia. These findings suggest that NT drugs can act as an effective opioid-free medication for the management of pain or can serve as adjuvant analgesics to reduce the opioid adverse effects.
BIOSEB Instruments Used
Dynamic Weight Bearing 2.0 (BIO-DWB-DUAL)
[meta_description] =>
[meta_keywords] => https://arxiv.org/ftp/arxiv/papers/2005/2005.01887.pdf
[meta_title] =>
[link_rewrite] => pain-relief-devoid-of-opioid-side-effects-following-central-action-of-a-silylated-neurotensin-analog
[actif_langue] => 1
[read] => 1236
[count_comments] => 0
[id] => 1269
[categories] => Array
(
[29] => Array
(
[id_prestablog_categorie] => 29
[title] => Neuropathic pain
[link_rewrite] => Neuropathic-pain
)
[10] => Array
(
[id_prestablog_categorie] => 10
[title] => Pain
[link_rewrite] => Pain
)
[2] => Array
(
[id_prestablog_categorie] => 2
[title] => Publications
[link_rewrite] => publications
)
)
[authors] =>
[paragraph_crop] => Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog
[link_for_unique] => 1
[products_liaison] => Array
(
[1216] => Array
(
[name] => Dynamic Weight Bearing 2.0
[description_short] => The advanced version of our Dynamic Weight Bearing Test for rodents (rats and mice) allows for faster paw identification, based on a video solution taking advantage of the most advanced algorithms of morphologic analysis, weight distribution and postural changes in dynamic conditions. An efficient and advanced alternative to traditional incapacitance tests (i.e. the paw pressure test or the force plate test) for assessing pain sensitivity in your research on analgesia, hyperalgesia and nociception involving rats and mice, including work on osteoarthritis, bone cancer, analgesic substances, Parkinson disease, allodynia...


[thumb] =>
[img_empty] => /var/www/vhosts/de3310.ispfr.net/bioseb2024/modules/prestablog/views/img/product_link_white.jpg
[image_presente] => 1
[link] => https://bioseb.com/en/pain-spontaneous-pain-postural-deficit/1216-dynamic-weight-bearing-20.html
)
[1877] => Array
(
[name] => Dynamic Weight Bearing 2.0 – Postural Module [Add-on]
[description_short] => Expand Your Analysis with Advanced Postural and Locomotor Calculations
BIOSEB’s renowned Dynamic Weight Bearing (DWB2) system is now more powerful than ever with the addition of the Postural Module. This optional software upgrade extends standard weight-bearing analysis by integrating unique calculations designed to quantify subtle aspects of postural balance, locomotor patterns, and compensatory behaviors.
Developed in collaboration with Dr. Tighilet’s lab from Aix Marseille Université-CNRS, the Postural Module improves your DWB2, providing valuable endpoints for studies on pain, neurology, vestibular dysfunction, and neurodegenerative disorders.


[thumb] =>
[img_empty] => /var/www/vhosts/de3310.ispfr.net/bioseb2024/modules/prestablog/views/img/product_link_white.jpg
[image_presente] => 1
[link] => https://bioseb.com/en/pain-spontaneous-pain-postural-deficit/1877-dynamic-weight-bearing-20-add-on-postural-module.html
)
)
)
1 Read more